Expression of Protein Tyrosine Phosphatase Non-receptor Type 23 in Hepatocellular Carcinoma Tissues and its Relationship with the Efficacy of Transcatheter Arterial Chemoembolization
LI Bao-ping, XU Jun
Department of Oncology,Xianyang Central Hospital,Xianyang Shaanxi 712000
Abstract 【Objective】To investigate the expression of protein tyrosine phosphatase non-receptor type 23 (PTPN23) in hepatocellular carcinoma (HCC) tissues and its relationship with the efficacy of transcatheter arterial chemoembolization (TACE). 【Methods】A total of 102 patients with HCC who were treated in the two hospitals were selected as the research subjects. Western blot was used to detect the expression of PTPN23 protein in HCC tissues; the modified response evaluation criteria in solid tumor (mRECIST) was used to evaluate the efficacy of TACE treatment. The relationship between the PTPN23 level in HCC tissues and the therapeutic effect of TACE was analyzed. 【Results】After TACE treatment in 102 HCC patients,18 patients (17.65%) CR,33 (32.35%) PR,21 (20.59%) SD and 30 (29.41%) PD. The PTPN23 protein level in the treatment ineffective group (n=30) was 0.80±0.18,which was lower than that in the treatment effective group 1.07±0.23,and the difference was statistically significant (P<0.05).The area under the ROC curve,sensitivity and specificity of PTPN23 to evaluate the efficacy of TACE treatment were 0.819,70.00% and 79.17%,respectively. Multivariate Logistic regression analysis showed that tumor diameter≥5 cm and PTPN23<0.90 were independent risk factors for TACE treatment (P<0.05). 【Conclusion】The detection of PTPN23 expression in HCC tissues is helpful to judge the efficacy of TACE treatment. Low expression of PTPN23 in HCC tissues is an independent risk factor for the efficacy of TACE therapy.
LI Bao-ping,XU Jun. Expression of Protein Tyrosine Phosphatase Non-receptor Type 23 in Hepatocellular Carcinoma Tissues and its Relationship with the Efficacy of Transcatheter Arterial Chemoembolization[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(8): 1178-1181.
[1] LLOVET J M,BRUIX J. Systematic review of randomized trials for unresectable hepatocellular carcinoma:Chemoembolization improves survival[J].Hepatology,2003,37(2):429-442.
[2] 孙伟航,张骜丹,李巍.预后营养指数联合磁共振表观扩散系数在肝细胞癌肝动脉化疗栓塞中的临床应用价值[J].中华医学杂志,2019,99(33):2581-2585.
[3] LU H Y,CHU H X,TAN Y X,et al. Novel ADAM-17 inhibitor ZLDI-8 inhibits the metastasis of hepatocellular carcinoma by reversing epithelial-mesenchymal transition in vitro and in vivo[J].Life Sci,2020,244:117343.
[4] van der LELY L,HÄFLIGER J,MONTALBAN-ARQUES A,et al. Loss of PTPN23 promotes proliferation and epithelial-to-mesenchymal transition in human intestinal cancer cells[J].Inflamm Intest Dis,2019,4(4):161-173.
[5] 中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版)[J].中华肝脏病杂志,2017,25(12):886-895.
[6] 中国医师协会介入医师分会.中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南[J].中华医学杂志,2018,98(47):3811-3819.
[7] LENCIONI R,LLOVET J M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J].Semin Liver Dis,2010,30(1):52-60.
[8] ZHENG S,CHEN Y,ZHENG S,et al. Inhibition of Mastermind-like 1 alleviates liver fibrosis induced by carbon tetrachloride in rats[J].Exp Biol Med (Maywood),2018,243(14):1099-1108.
[9] 翟天宇,王健东.MRI评估肝细胞癌经导管动脉化疗栓塞术疗效的研究进展[J].中华解剖与临床杂志,2017,22(3):244-247.
[10] 李红,尹芳,罗贯虹,等.异常糖链糖蛋白与甲胎蛋白在肝癌诊断及预后评估中的应用价值[J].胃肠病学和肝病学杂志,2019,28(11):1221-1224.
[11] 蒋奕,王惠临.中性粒细胞/淋巴细胞比值评估肿瘤预后价值的研究进展[J].中国癌症防治杂志,2016,8(5):329-332.
[12] KIM S S,NAM J S,CHO H J,et al. Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma[J].J Gast Hep,2017,32(1):199-207.
[13] MA C,HUANG S,XU L,et al. Transcription co-activator P300 activates Elk1-aPKC-ι signaling mediated epithelial-to-mesenchymal transition and malignancy in hepatocellular carcinoma[J].Oncogenesis,2020,9(3):32.
[14] 文军,刘丽,徐向贤,等.雷替曲塞经TACE治疗原发性肝癌的临床疗效分析[J].介入放射学杂志,2019,28(2):175-178.
[15] 刘光华,俞炬明,范国平,等.肝细胞癌患者伴发糖尿病行肝动脉化疗栓塞术的预后因素分析[J].介入放射学杂志,2017,26(10):926-930.
2022, Vol. 39 
